ICT 121

Drug Profile

ICT 121

Alternative Names: ICT-121

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator ImmunoCellular Therapeutics
  • Developer Cedars-Sinai Health System; ImmunoCellular Therapeutics
  • Class Cancer vaccines; Dendritic cell vaccines; Peptide vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma

Most Recent Events

  • 25 Jul 2016 ImmunoCellular Therapeutics completes enrolment in its phase I trial for Glioblastoma in USA
  • 19 May 2016 Phase-I development is ongoing in USA
  • 30 Jul 2013 Phase-I clinical trials in recurrent Glioblastoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top